

Special Issue

Eosinophils and Associated Disorders: From Basic Science to Therapeutic Perspectives

Message from the Guest Editors

Eosinophils have been subdivided into different subpopulations with distinct phenotypes and functions, namely, resident and inflammatory eosinophils. Growing evidence now reveals a role for eosinophils not only in asthma but also in autoimmune diseases and vasculitis as well as in hypereosinophilic syndromes. Their presence in inflammatory tissues is a hallmark of the type 2 inflammatory response. Eosinophils primed by interleukin (IL)-5, IL-3, granulocyte macrophage colony-stimulating factor (GM-CSF), and eotaxins can express membrane receptors and adhesion molecules involved in activation and tissue migration. Treatment of eosinophilic diseases has traditionally been through nonspecific eosinophil attenuation via the use of glucocorticoids. However, several novel biologic therapies targeting eosinophil maturation factors, such as IL-5 and IL-5R or IL-4/IL-13R, have recently been approved for clinical use. The aim of this Special Issue is to highlight new findings on the physiological and pathophysiological roles of eosinophils in the various pathologies in which they are involved and discuss current and future therapeutic strategies.

Guest Editors

Dr. Andrea Matucci

Immunology Unit, Careggi University Hospital, 50134 Florence, Italy

Dr. Alessandra Vultaggio

Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/152556

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).